Analysts Set Precigen, Inc. (NASDAQ:PGEN) PT at $7.00

Shares of Precigen, Inc. (NASDAQ:PGEN) have received a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $7.00.

A number of analysts recently issued reports on PGEN shares. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Precigen in a research report on Friday, November 15th. JMP Securities dropped their target price on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating for the company in a research report on Thursday, August 15th.

Precigen Price Performance

PGEN opened at $0.86 on Friday. The firm has a 50 day moving average price of $0.89 and a 200 day moving average price of $1.20. Precigen has a 1 year low of $0.77 and a 1 year high of $1.93.

Hedge Funds Weigh In On Precigen

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Precigen by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock worth $9,814,000 after acquiring an additional 19,875 shares during the period. Iridian Asset Management LLC CT boosted its holdings in Precigen by 82.5% in the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after acquiring an additional 1,706,815 shares during the period. Geode Capital Management LLC boosted its holdings in Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after acquiring an additional 149,829 shares during the period. State Street Corp boosted its holdings in Precigen by 1.0% in the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock worth $2,720,000 after acquiring an additional 29,253 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Precigen by 11.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after acquiring an additional 127,467 shares during the period. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.